Difference between revisions of "Mitotane (Lysodren)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
||
| (6 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| Line 13: | Line 13: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| + | *1970-07-08: Approved for the treatment of inoperable, functional or nonfunctional, [[Adrenocortical carcinoma|adrenal cortical carcinoma]]. | ||
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
| − | * | + | *2004-04-28: Indicated for symptomatic treatment of advanced (unresectable, metastatic or relapsed) [[Adrenocortical carcinoma|adrenal cortical carcinoma]]. The effect of Lysodren on non-functional adrenal cortical carcinoma is not established. ''(No supporting studies are cited)'' |
==Also known as== | ==Also known as== | ||
| − | *'''Generic name:''' o, | + | *'''Generic name:''' o,p'-DDD |
*'''Brand name:''' Lysodren | *'''Brand name:''' Lysodren | ||
Latest revision as of 00:59, 29 June 2024
General information
Class/mechanism: Adrenal cytotoxic agent, suppresses adrenal cortex and the extra-adrenal metabolism of cortisol.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 1970-07-08: Approved for the treatment of inoperable, functional or nonfunctional, adrenal cortical carcinoma.
History of changes in EMA indication
- 2004-04-28: Indicated for symptomatic treatment of advanced (unresectable, metastatic or relapsed) adrenal cortical carcinoma. The effect of Lysodren on non-functional adrenal cortical carcinoma is not established. (No supporting studies are cited)
Also known as
- Generic name: o,p'-DDD
- Brand name: Lysodren